Publications for Mikael Chéramy
Co-author map based on ISI articles 2007-

Publications mentioned in social media 6 times*

Keywords

trial treatment t secretion recent-onset placebo patients insulin immune iii gada gad-alum gad(65) doses diabetes children cells c-peptide 30 15

Journal Articles

Johnny Ludvigsson, Mikael Chéramy, Stina Axelsson, Mikael Pihl, Linda Åkerman and Rosaura Casas
  GAD-treatment of children and adolescents with recent-onset Type 1 diabetes preserves residual insulin secretion after 30 months
 
Altmetric usage: 1

  Diabetes/Metabolism Research Reviews, 2014, 30(5), 405-414.
 Web of Science® Times Cited: 1

Stina Axelsson, Mikael Cheramy, Linda Åkerman, Mikael Pihl, Johnny Ludvigsson and Rosaura Casas
  Cellular and Humoral Immune responses in Type 1 Diabetic patients participating in a Phase III GAD-alum Intervention Trial
  Diabetes Care, 2013, 36(11), 3418-3424.
   Fulltext  PDF  
 Web of Science® Times Cited: 2

Mikael Pihl, Linda Åkerman, Stina Axelsson, Mikael Chéramy, Maria Hjorth, R. Mallone, Johnny Ludvigsson and Rosaura Casas
  Regulatory T cell phenotype and function 4 years after GAD–alum treatment in children with type 1 diabetes
 
Altmetric usage: 1

  Clinical and Experimental Immunology, 2013, 172(3), 394-402.
   Fulltext  PDF  
 Web of Science® Times Cited: 1

Mikael Chéramy, Christiane S. Hampe, Johnny Ludvigsson and Rosaura Casas
  Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals
  Clinical and Experimental Immunology, 2013, 171(3), 247-254.
   Fulltext  PDF  
 Web of Science® Times Cited: 1

Camilla Skoglund, Mikael Chéramy, Rosaura Casas, Johnny Ludvigsson and Christiane S Hampe
  GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes
  Pediatric Diabetes, 2012, 13(3), 244-250.
 Web of Science® Times Cited: 2

Stina Axelsson, Mikael Chéramy, Maria Hjorth, Mikael Pihl, Linda Åkerman, Emanuela Martinuzzi, Roberto Mallone, Johnny Ludvigsson and Rosaura Casas
  Long-Lasting Immune Responses 4 Years after GAD-Alum Treatment in Children with Type 1 Diabetes
 
Altmetric usage: 2

  PLoS ONE, 2011, 6(12), .
   Fulltext  PDF  
 Web of Science® Times Cited: 15

Johnny Ludvigsson, Maria Hjorth, Mikael Chéramy, Stina Axelsson, Mikael Pihl, G Forsander, N-O Nilsson, B-O Samuelsson, T Wood, J Aman, E Ortqvist and Rosaura Casas
  Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial
  DIABETOLOGIA, 2011, 54(3), 634-640.
   Fulltext  PDF  
 Web of Science® Times Cited: 28

Mikael Pihl, Mikael Chéramy, Jenny Mjösberg, Johnny Ludvigsson and Rosaura Casas
  Increased expression of regulatory T cell-associated markers in recent-onset diabetic children
  Open Journal of Immunology, 2011, 1(3), 57-64.
   Fulltext  PDF  

Mikael Chéramy, Camilla Skoglund, Ingela Johansson, Johnny Ludvigsson, Christiane S Hampe and Rosaura Casas
  GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD(65) enzyme activity and humoral response
  Clinical Immunology, 2010, 137(1), 31-40.
   Fulltext  PDF  
 Web of Science® Times Cited: 20

Johnny Ludvigsson, Maria Faresjö, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl, Outi Vaarala, Gun Forsander, Sten Ivarsson, Calle Johansson, Agne Lindh, NO Nilsson, Jan Åman, Eva Örtqvist, Peter Zerhouni and Rosaura Casas
  GAD treatment and insulin secretion in recent-onset type 1 diabetes
 
Altmetric usage: 2

  New England Journal of Medicine, 2008, 359(18), 1909-1920.
 Web of Science® Times Cited: 235

Conference Articles

E Martinuzzi, M C Gagnerault, S Fourlanos, L Harrison, Stina Axelsson, Mikael Chéramy, Johnny Ludvigsson, Rosaura Casas and R Mallone
  Why are the benefits of vaccinations in the helping of beta-cellular antigenes in type 1 diabetes so limited? An analysis of linked immunological biomarkers in DIABETES and METABOLISM, vol 38, issue 2, pp A5-A5
  DIABETES and METABOLISM, 2012.


Rosaura Casas, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl and Johnny Ludvigsson
  Specific immunomodulatory effect of GAD(65) in type 1 diabetics
  in DIABETOLOGIA, vol 52, 2009.


Johnny Ludvigsson, Camilla Skoglund, Mikael Chéramy, Rosaura Casas and C Hampe
  GAD(65) treatment induces high GADA but no changes in epitopes or adverse signs/symptoms in type 1 diabetic children
  in DIABETOLOGIA, vol 52., 2009.


Ph.D. Theses

Mikael Chéramy
  Characteristics of GADA in Type 1 Diabetes following Immunomodulation with GAD65
  2012.


  Fulltext PDF

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.